Serum HER2 testing in patients with HER2-positive breast cancer: The death knell tolls

The Lancet Oncology

Volumn 12, Issue 3, 2011, Pages 286-295

  Leyland Jones, Brian ^a   Smith, Brian R ^b  

^a EMORY UNIVERSITY   (United States)

^b VM Institute of Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; PACLITAXEL; PLACEBO; TAXANE DERIVATIVE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL DECISION MAKING; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TARGETING; GENETIC TRANSFECTION; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; QUALITY OF LIFE; REVIEW;

BREAST NEOPLASMS; FEMALE; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 79952035138     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70297-7     Document Type: Review

References (90)

1. Alroy I, Yarden Y Biochemistry of HER2 oncogenesis in breast cancer. Breast Dis 2000, 11:31-48.
2. Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. Embo J 1997, 16:1647-1655.
3. Fry MJ Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?. Breast Cancer Res 2001, 3:304-312.
4. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
5. Owens MA, Horten BC, Da Silva MM HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004, 5:63-69.
6. Sjögren S, Inganas M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998, 16:462-469.
7. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
8. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990, 8:103-112.
9. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000, 92:1991-1998.
10. Dowsett M Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endoc Relat Cancer 2001, 8:191-195.
11. Herceptin prescribing information. Genentech 2008.
12. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
13. Zabrecky JR, Lam T, McKenzie SJ, et al. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991, 266:1716-1720.
14. Pupa SM, Menard S, Morelli D, et al. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 1993, 8:2917-2923.
15. Codony-Servat J, Albanell J, Lopez-Talavera JC, et al. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999, 59:1196-1201.
16. Molina MA, Codony-Servat J, Albanell J, et al. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001, 61:4744-4749.
17. Xia W, Chen JS, Zhou X, et al. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 2004, 10:3815-3824.
18. Leitzel K, Teramoto Y, Sampson E, et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 1992, 10:1436-1443.
19. Carlson RW, Moench SJ, Hammond ME, et al. NCCN HER2 Testing in Breast Cancer Task Force. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006, 4(suppl 3):1-22.
20. Colomer R, Llombart-Cussac A, Lloveras B, et al. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study. Cancer 2007, 110:2178-2275.
21. Molina R, Jo J, Filella X, et al. C-erbB-2 CEA and CA 15.3 serum levels in the early diagnosis of recurrence in breast cancer patients. Anticancer Res 1999, 19:2551-2556.
22. Thriveni K, Deshmane V, Bapsy PP, et al. Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients. Indian J Med Res 2007, 125:137-142.
23. Jensen BV, Johansen JS, Price PA High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 2003, 9:4423-4434.
24. Köstler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 2004, 10:1618-1624.
25. Müller V, Witzel I, Lück HJ, et al. Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 2004, 86:9-18.
26. Pichon MF, Hacene K, Guepratte S, et al. Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients. Clin Lab 2004, 50:163-170.
27. Saghatchian M, Guepratte S, Hacene K, et al. Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers 2004, 19:14-22.
28. Classen S, Kopp R, Possinger K, et al. Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy. Tumour Biol 2002, 23:70-75.
29. Christianson TA, Doherty JK, Lin YJ, et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Research 1998, 15:5123-5129.
30. Brodowicz T, Wiltschke C, Budinsky A, et al. Soluble HER-2/Neu neutralizes biologic effects of anti-HER-2/Neu antibody on breast cancer cells in vitro. Int J Cancer 1997, 73:875-879.
31. Ghedini GC, Ciravolo V, Tortoreto M, et al. Shed HER2 extracellular domain in HER2-mediated tumour growth and in trastuzumab sensitivity. J Cellular Physiology 2010, 225:356-365.
32. Vazquez-Martin A, Fernandez-Real JM, Oliveras-Ferraros C, et al. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients. Int J Oncol 2009, 35:1369-1376.
33. Ludovini V, Gori S, Colozza M, et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol 2008, 19:883-890.
34. Bramwell VHC, Doig GS, Tuck AB, et al. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Res Treat 2009, 114:503-511.
35. Garoufali A, Kyriakou F, Kountourakis P, et al. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer. J BUON 2008, 13:409-413.
36. Hicks DG, Kulkarni S HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol 2008, 129:263-273.
37. Colomer R, Montero S, Lluch A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000, 6:2356-2362.
38. Fornier MN, Seidman AD, Schwartz MK, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005, 16:234-239.
39. Im SA, Kim SB, Lee MH, et al. Docetaxel plus epirubicin as first-line chemotherapy in domain and vascular endothelial growth factor. Oncol Rep 2005, 14:481-487.
40. Kong SY, Nam BH, Lee KS, et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin Chem 2006, 52:1510-1515.
41. Tse C, Brault D, Gligorov J, et al. Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. Clin Chem 2005, 51:1093-1101.
42. Krainer M, Brodowicz T, Zellinger R, et al. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology 1997, 54:475-481.
43. Molina R, Filella X, Zanon G, et al. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. Anticancer Res 2003, 23:1043-1050.
44. Cheung KL, Pinder SE, Paish C, et al. The role of blood tumor marker measurement (using a biochemical index score and c-erbB2) in directing chemotherapy in metastatic breast cancer. Int J Biol Markers 2000, 15:203-209.
45. Pallud C, Guinebretiere JM, Guepratte S, et al. Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours. Anticancer Res 2005, 25:1433-1440.
46. Pribylová O, Springer D, Vítková I, et al. HER-2 tissue expression correlated with serum levels in breast cancer patients. Folia Biol (Praha) 2007, 53:129-133.
47. Sandri MT, Johansson H, Colleoni M, et al. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anticancer Res 2004, 24:1261-1266.
48. Schippinger W, Regitnig P, Bauernhofer T, et al. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Oncol Rep 2004, 11:1331-1336.
49. Kong SY, Kang JH, Kwon Y, et al. Serum HER2-2 concentration in patients with primary breast cancer. J Clin Pathol 2006, 59:373-376.
50. Leitzel K, Chaudri-Ross HA, Evans DB, et al. Elevated pretreatment plasma HER2/neu and decreased response to neoadjuvant letrozole and tamoxifen. Proc Breast Cancer Symposium 2007, 113. abstr 108.
51. Goksel G, Taneli F, Uslu R, et al. Serum her-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer. J Int Med Res 2007, 35:165-172.
52. Narita T, Funahashi H, Satoh Y, et al. C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 1992, 24:97-102.
53. Willsher PC, Beaver J, Pinder S, et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 1996, 40:251-255.
54. Dinocca S, Blot E, Laberge-Le-Couteulx S, et al. Serum level of HER2 extra cellular domain (ECD) is a significant prognostic factor for survival in metastatic breast cancer without HER2 overexpression on primary tumor. Breast Cancer Res Treat 2006, 100(suppl 1). abstr 50.
55. Esteva FJ, Cheli CD, Fritsche H, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 2005, 7:436-443.
56. Breuer B, De Vivo I, Luo JC, et al. erbB-2 and myc oncoproteins in sera and tumors of breast cancer patients. Cancer Epidemiol Biomarkers Prev 1994, 3:63-66.
57. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology - Breast Cancer, (accessed Jan 5, 2011). http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.
58. Leary AF, Hanna WH, van de Vijver MJ, et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol 2009, 27:1694-1705.
59. Lüftner D, Henschke P, Flath B, et al. Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer. Anticancer Res 2004, 24:895-906.
60. Cameron D, Casey M, Press M, et al. A phase III randomised comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008, 112:533-543.
61. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
62. Osoba D, Slamon DJ, Burchmore M, et al. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002, 20:3106-3113.
63. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
64. Marty M, Cognetti F, Maraninchi D, et al. Superior long-term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: patients surviving more than 4 years in the M77001 study. Breast Cancer Res Treat 2006, 100(suppl 1). abstr 2067.
65. Slamon DJ, Eiermann W, Robert N, et al. BCIRG 006: phase III trial comparing AC→T with AC→TH and with TCH in the adjuvant treatment of HER2-positive early breast cancer patients: second interim efficacy analysis. Breast Cancer Res Treat 2006, 100(suppl 1). abstr 53.
66. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Proc Soc Am Clin Oncol 2007, 25(suppl 18). abstr 512.
67. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007, 369:29-36.
68. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446.
69. Mimura K, Kono K, Hanawa M, et al. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 2005, 11:4898-4904.
70. Izumi Y, Xu L, di Timaso E, et al. Tumor biology: Herceptin acts as an antiangiogenic cocktail. Nature 2002, 416:279-280.
71. Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994, 9:1829-1838.
72. Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA reactive drugs. Oncogene 1998, 17:2235-2249.
73. Pietras RJ, Poen JC, Gallargo D, et al. Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999, 59:1347-1355.
74. Austin CD, De Maziere AM, Pisacane PI, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004, 15:5268-5282.
75. Bethune-Volters A, Labroquere M, Guepratte S, et al. Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients. Anticancer Res 2004, 24:1083-1089.
76. Lennon S, Barton C, Banken L, et al. Utility of serum HER2 extracellular domain (ECD) assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol 2009, 27:1685-1693.
77. Leyland-Jones B, Marty M, Baselga J, et al. Effects of trastuzumab (H) and chemotherapy on circulating HER2 extracellular domain (ECD) in patients with metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC). Proc Soc Am Clin Oncol 2004, 23. abstr 570.
78. Valero V, Roche H, Pienkowski T, et al. BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer. Proc Soc Am Clin Oncol 2007, 25. abstr 1020.
79. Mazouni C, Hall A, Broglio K, et al. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 2007, 109:496-501.
80. Köstler WJ, Steger GG, Soleiman A, et al. Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. Anticancer Res 2004, 24:1127-1130.
81. Ali SM, Carney WP, Esteva FJ, et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Proc Soc Am Clin Oncol 2006, 24(suppl 18). abstr 500.
82. Baselga J, Carbonell X, Castañeda-Soto N-J, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005, 23:2162-2171.
83. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003, 21:2889-2895.
84. Leyland-Jones B, Gelmon K, Ayoub JP, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003, 21:3965-3971.
85. Bianchi G, Albanell J, Eiermann W, et al. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res 2003, 9:5944-5951.
86. Tykerb prescribing information. GlaxoSmithKline, 2008.
87. Lipton A, Carney W, Martin A-M, et al. Serum levels of HER2/neu extracellular domain (ECD) in clinical studies with lapatinib in HER2/neu-positive metastatic breast cancer (MBC). Proc Breast Symposium 2007, 111. abstr 105.
88. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008, 112:533-543.
89. Finn RS, Gagnon R, Di Leo A, et al. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol 2009, 27:5552-5558.
90. Scaltriti M, Chandarlapaty S, Prudkin L, et al. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast cancer co-expressing the truncated p95 HER2 receptor. Clin Cancer Res 2010, 16:2688-2695.